Artwork

Conteúdo fornecido por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

The REFINE trial: How can we improve the way we give cancer immunotherapy?

16:57
 
Compartilhar
 

Manage episode 371570705 series 1631392
Conteúdo fornecido por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects. In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs. - Further information is available on the REFINE study page at www.mrcctu.ucl.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/3DgIDE2 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: https://forms.office.com/e/PjfjQ5Mn6g
  continue reading

25 episódios

Artwork
iconCompartilhar
 
Manage episode 371570705 series 1631392
Conteúdo fornecido por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects. In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs. - Further information is available on the REFINE study page at www.mrcctu.ucl.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/3DgIDE2 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: https://forms.office.com/e/PjfjQ5Mn6g
  continue reading

25 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências

Ouça este programa enquanto explora
Reproduzir